The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3′, 3′-dimethylsuccinyl}-betulinic acid

被引：62

作者：

Zhou J. ^{[1
]}

Chen C.H. ^{[2
]}

Aiken C. ^{[1
]}

机构：

[1] Dept. of Microbiology and Immunology, Vanderbilt Univ. School of Medicine, Nasville, TN

[2] Department of Pathology, Duke University Medical Center, Durham, NC

来源：

Retrovirology | / 1卷 / 1期

关键词：

Differential Sensitivity; Betulinic Acid; Proviral Clone; Calcium Phosphate Coprecipitation Method;

D O I：

10.1186/1742-4690-1-15

中图分类号：

学科分类号：

摘要：

Background. Despite the effectiveness of currently available antiretroviral therapies in the treatment of HIV-1 infection, a continuing need exists for novel compounds that can be used in combination with existing drugs to slow the emergence of drug-resistant viruses. We previously reported that the small molecule 3-O-{3′,3′-dimethylsuccinyl}-betulinic acid (DSB) specifically inhibits HIV-1 replication by delaying the processing of the CA-SP1 junction in Pr55Gag. By contrast, SIVmac239 replicates efficiently in the presence of high concentrations of DSB. To determine whether sequence differences in the CA-SP1 junction can fully account for the differential sensitivity of HIV-1 and SIV to DSB, we engineered mutations in this region of two viruses and tested their sensitivity to DSB in replication assays using activated human primary CD4+ T cells. Results. Substitution of the P2 and P1 residues of HIV-1 by the corresponding amino acids of SIV resulted in strong resistance to DSB, but the mutant virus replicated with reduced efficiency. Conversely, replication of an SIV mutant containing three amino acid substitutions in the CA-SP1 cleavage site was highly sensitive to DSB, and the mutations resulted in delayed cleavage of the CA-SP1 junction in the presence of the drug. Conclusions. These results demonstrate that the CA-SP1 junction in Pr55Gag represents the primary viral target of DSB. They further suggest that the therapeutic application of DSB will be accompanied by emergence of mutant viruses that are highly resistant to the drug but which exhibit reduced fitness relative to wild type HIV-1. © 2004 Zhou et al; licensee BioMed Central Ltd.

引用

页数：10

共 13 条

[1]

Vogt V.M., Proteolytic processing and particle maturation, Curr. Top Microbiol. Immunol., 214, pp. 95-131, (1996)

[2]

Wiegers K., Rutter G., Kottler H., Tessmer U., Hohenberg H., Krausslich H.-G., Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites, J. Virol., 72, pp. 2846-2854, (1998)

[3]

Kanamoto T., Kashiwada Y., Kanbara K., Gotoh K., Yoshimori M., Goto T., Sano K., Nakashima H., Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation, Antimicrob. Agents Chemother., 45, pp. 1225-1230, (2001)

[4]

Li F., Goila-Gaur R., Salzwedel K., Kilgore N.R., Reddick M., Matallana C., Castillo A., Zoumplis D., Martin D.E., Orenstein J.M., Allaway G.P., Freed E.O., Wild C.T., PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing, Proc. Natl. Acad. Sci. U. S. A., 100, pp. 13555-13560, (2003)

[5]

Zhou J., Yuan X., Dismuke D., Forshey B.M., Lundquist C., Lee K.H., Aiken C., Chen C.H., Small-Molecule Inhibition of Human Immunodeficiency Virus Type 1 Replication by Specific Targeting of the Final Step of Virion Maturation, J. Virol., 78, pp. 922-929, (2004)

[6]

Accola M.A., Hoglund S., Gottlinger H.G., A putative a-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly, J. Virol., 72, pp. 2072-2078, (1998)

[7]

Lundquist C.A., Tobiume M., Zhou J., Unutmaz D., Aiken C., Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes, J. Virol., 76, pp. 4625-4633, (2002)

[8]

Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A., Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone, J. Virol., 59, pp. 284-291, (1986)

[9]

Chen C., Okayama H., High-efficiency tranformation of mammalian cells by plasmid DNA, Mol. Cell Biol., 7, pp. 2745-2752, (1987)

[10]

Charneau P., Alizon M., Clavel F., A second origin of DNA plus-strand synthesis is required for optimal human immunodeficiency virus replication, J. Virol., 66, pp. 2814-2820, (1992)

← 1 2 →